Jonathan Wesley Riess, M.D., M.S. for ...

Dr. Jonathan W. Riess

Claim this profile

University of California Davis Comprehensive Cancer Center

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
33 drugs studied

Area of expertise

1

Lung Cancer

Global Leader

Jonathan W. Riess has run 12 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III
2

Non-Small Cell Lung Cancer

Jonathan W. Riess has run 10 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III

Affiliated Hospitals

Image of trial facility.

University Of California Davis Comprehensive Cancer Center

Image of trial facility.

University Of California, Davis

Clinical Trials Jonathan W. Riess is currently running

Image of trial facility.

Osimertinib + Chemotherapy

for Lung Cancer

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.

Recruiting

1 award

Phase 2

9 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

More about Jonathan W. Riess

Clinical Trial Related

6 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Jonathan W. Riess has experience with

  • Osimertinib
  • Carboplatin
  • Pembrolizumab
  • Cisplatin
  • Trastuzumab Deruxtecan
  • Erlotinib Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jonathan W. Riess specialize in?

Is Jonathan W. Riess currently recruiting for clinical trials?

Are there any treatments that Jonathan W. Riess has studied deeply?

What is the best way to schedule an appointment with Jonathan W. Riess?

What is the office address of Jonathan W. Riess?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security